Goki Suda

Alcohol involvement may modify the association between previous hepatitis B virus infection and hepatocellular carcinoma risk in steatotic liver disease.

Journal: Journal of gastroenterology

Published: May 05, 2026

Competing risks of treatment discontinuation of atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.

Journal: JHEP reports : innovation in hepatology

Published: March 10, 2026

Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 07, 2026

HBsAg glycan isomer predicts on-treatment HBsAg decline in low-HBsAg chronic hepatitis B on nucleos(t)ide therapy.

Journal: Virology journal

Published: February 03, 2026

Cachexia in Cirrhosis Is Characterized by Sex-Specific Loss of Muscle Mass and Adipose Tissue.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: December 14, 2025

Corticosteroid rescue of immune checkpoint inhibitor-induced hepatitis triggers HCV reactivation in HCV-related HCC.

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 22, 2025

Tenofovir alafenamide prevents HBV reactivation in anticancer/immunosuppression: 24-month multicentre prospective study.

Journal: The Journal of infection

Published: November 21, 2025

Serum fibroblast growth factor 21 is a novel biomarker of cachexia in chronic liver disease.

Journal: Frontiers in nutrition

Published: October 23, 2025

Circulating cfDNA CD86 methylation is associated with durable response to atezolizumab-bevacizumab in hepatocellular carcinoma.

Journal: Hepatology international

Published: October 22, 2025

Prevalence and Prognostic Impact of the Coexistence of Cachexia and Sarcopenia in Patients With Chronic Liver Diseases.

Journal: Journal of cachexia, sarcopenia and muscle

Published: October 20, 2025

Simplified monitoring of sofosbuvir/velpatasvir in Japanese patients with chronic hepatitis C based on a retrospective analysis of a prospective multicenter cohort.

Journal: Scientific reports

Published: September 19, 2025

Soluble Cluster of Differentiation 14 as a Prognostic Marker in Decompensated Cirrhosis With Water Retention.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: August 26, 2025

Alcohol involvement may modify the association between previous hepatitis B virus infection and hepatocellular carcinoma risk in steatotic liver disease.

Alcohol involvement may modify the association between previous hepatitis B virus infection and hepatocellular carcinoma risk in steatotic liver disease.

Competing risks of treatment discontinuation of atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.

Competing risks of treatment discontinuation of atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.

Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab.

Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab.

HBsAg glycan isomer predicts on-treatment HBsAg decline in low-HBsAg chronic hepatitis B on nucleos(t)ide therapy.

HBsAg glycan isomer predicts on-treatment HBsAg decline in low-HBsAg chronic hepatitis B on nucleos(t)ide therapy.

Cachexia in Cirrhosis Is Characterized by Sex-Specific Loss of Muscle Mass and Adipose Tissue.

Cachexia in Cirrhosis Is Characterized by Sex-Specific Loss of Muscle Mass and Adipose Tissue.

Corticosteroid rescue of immune checkpoint inhibitor-induced hepatitis triggers HCV reactivation in HCV-related HCC.

Corticosteroid rescue of immune checkpoint inhibitor-induced hepatitis triggers HCV reactivation in HCV-related HCC.

Tenofovir alafenamide prevents HBV reactivation in anticancer/immunosuppression: 24-month multicentre prospective study.

Tenofovir alafenamide prevents HBV reactivation in anticancer/immunosuppression: 24-month multicentre prospective study.

Serum fibroblast growth factor 21 is a novel biomarker of cachexia in chronic liver disease.

Serum fibroblast growth factor 21 is a novel biomarker of cachexia in chronic liver disease.

Circulating cfDNA CD86 methylation is associated with durable response to atezolizumab-bevacizumab in hepatocellular carcinoma.

Circulating cfDNA CD86 methylation is associated with durable response to atezolizumab-bevacizumab in hepatocellular carcinoma.

Prevalence and Prognostic Impact of the Coexistence of Cachexia and Sarcopenia in Patients With Chronic Liver Diseases.

Prevalence and Prognostic Impact of the Coexistence of Cachexia and Sarcopenia in Patients With Chronic Liver Diseases.

Simplified monitoring of sofosbuvir/velpatasvir in Japanese patients with chronic hepatitis C based on a retrospective analysis of a prospective multicenter cohort.

Simplified monitoring of sofosbuvir/velpatasvir in Japanese patients with chronic hepatitis C based on a retrospective analysis of a prospective multicenter cohort.

Soluble Cluster of Differentiation 14 as a Prognostic Marker in Decompensated Cirrhosis With Water Retention.

Soluble Cluster of Differentiation 14 as a Prognostic Marker in Decompensated Cirrhosis With Water Retention.

Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab.

Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab.